Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Center-Al is an **alum-precipitated allergenic extract immunotherapy product** used for subcutaneous hyposensitization treatment of IgE-mediated respiratory and environmental allergies. It is prepared from aqueous allergenic extracts by forming an aluminum hydroxide precipitated complex and is supplied as a sterile multi-dose suspension containing 0.4% phenol preservative for physician-administered injection. The product is intended for allergen immunotherapy against sensitization to pollens, molds, inhalants, and epidermals, with the therapeutic effect arising from repeated exposure to clinically relevant allergen extracts to induce immune tolerance and reduce allergic reactivity over time. In the provided context, it is described as a biologic product distributed in Canada by ALK-Abelló Pharmaceuticals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Center-Al.